The TCS PIONEER Series is a curated IP training programme for innovators, entrepreneurs, and business leaders, offering practical insights into intellectual property strategy and commercialization. The seminar provides participants with practical training in key aspects of patent practice and strategy. Topics include identifying common patenting pitfalls, drafting strong patent specifications and claims, conducting prior art searches and patentability assessments, understanding freedom-to-operate considerations, and developing effective global filing strategies. Through interactive sessions that combine foundational principles with practical exercises and case studies, Jennifer and Pauli share their experience in international patent practice to help participants strengthen their understanding of patent law and innovation protection.

We are thrilled to be part of this initiative and look forward to the remaining sessions covering patent drafting and prosecution, prior art and freedom-to-operate analyses, and strategic filing and global patent protection.

Learn more about the programme: 🔗 TCS PIONEER Series Details

我們過去活動

Recommended Insights

Compositions Limited by Use: A Cautionary Tale

2022年10月26日
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

2021年6月9日
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

2018年11月23日
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]

Breaking: China Released Drug Trial Data Protection Implementation Measures

2026年5月22日
On May 15, 2026, China’s National Medical Products Administration (NMPA) officially announced the final Measures for the Implementation of Drug Trial Data Protection (“Measures”), effective May 15, 2026. These Measures provide important details supporting the recently announced Implementing Regulations of the Drug Administration Law (“Regulations” – also effective May 15, 2026), which formally introduced a […]
Top crossarrow-right